Off the wire
Aussie scientists to launch autonomous drones to gather ocean data  • Singapore's CPI rises 0.5 pct in February  • 2nd LD Writethru: U.S. suspends metals tariffs for EU, 6 other economies  • 1st LD: China warns U.S. against putting bilateral trade ties in jeopardy  • Digital taxation too low to be continued: EU  • Australia's largest warship sails into Melbourne  • Polling for 26 seats of Upper House of Indian parliament in 7 states begins  • China-India border affairs meeting held in New Delhi  • 9 IS militants killed in eastern Afghan airstrikes  • Shark warnings issued as 150 whales stranded on beach in Western Australia  
You are here:  

Revolutionary! Stem cell therapy restores sight of two patients

Xinhua,March 23, 2018 Adjust font size:

LONDON, March 23 (Xinhua) -- Scientists have helped two patients regain vision from age-related macular degeneration (AMD) with a clinical trial of a stem cell therapy, offering a glimmer of hope for the treatment of a common cause of blindness.

The two patients, a woman in her 60s and a man in his 80s, each had one eye implanted with a patch of stem cells. The number of letters each of them could read correctly off an eye chart increased dramatically after the procedure.

The breakthrough, published earlier this week in Nature Biotechnology, was made by the London Project to Cure Blindness, a collaboration between University of College London and Moorfields Eye Hospital.

"In the months before the operation my sight was really poor and I couldn't see anything out of my right eye," 86-year-old Douglas Waters was quoted by the Guardian as saying. "After the surgery my eyesight improved to the point where I can now read the newspaper and help my wife out with the gardening."

There are two forms of macular degeneration, "wet" and "dry," with similar problems. In the advanced condition of AMD, retinal pigment epithelium cells in people's retinas die off, leading to macular degeneration and vision loss.

The team planned to treat 10 people who had the "wet" form of AMD, caused by sudden blood vessels leakage in the eye.

"While this is only a very early clinical trial, the results are positive and show that the technology is moving along in the right direction," Carmel Toomes, associate professor at the Leeds Institute of Molecular Medicine, was quoted by the Guardian as saying.

Scientists believe the procedure could be a common surgery in the near future. It's not clear how much it would cost. Enditem